AAV Capsid Engineering
CARE™ explores novel AAV vectors with improved on-target specificity offering clinical safety.
팝업레이어 알림
PREV
NEXT
SCROLL
PIPELINE
| Candidate | Indication | Development status | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|||
| Rare Genetic Disease | GXC-301 | Lafora disease |
In Vivo
ODD & RPDD granted by US FDA
|
|||
| GXC-302 | Undisclosed |
In Vitro
|
||||
| GXC-303 | ALS |
In Vivo
|
||||
| GXC-304 | Fronto Temporal Dementia |
In Vivo
|
||||
좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.
NOTICE
VIEW MORE
NEWS
VIEW MORE
-
NEWS
2026-06-12
Genixcure Recruited Han Seung-il, an expert in structural biology from 'Pfizer', respectively
Strengthen global business development and technology commercialization capabilities...Accelerate global technology transfer and strategic partnership expansionAcquire a machine learning-based AAV capsid design platform and next-generation CNS target vectorGenixCure announced on the 11th that it has appointed a representative from Han Seung-il to strengthen its global business development (BD) and technology commercialization capabilities.Han Seung-il is an expert in "structural biology" who has conducted structural-based new drug development and vaccine and therapeutic research for more than 20 years at the Pfizer Research and Development (R&D) organization. In particular, it has contributed to various innovative therapeutic R&D based on its accumulated experience in the field of protein structure analysis and structure-based design.GenixCure is developing AAV vectors that target not only the central nervous system (CNS) but also muscle and eye tissue through 'InsightMiner', an artificial intelligence (AI)-based adeno-associated virus (AAV) capsid development platform. Recently, we have secured a next-generation AAV capsid that exhibits superior CNS target performance and delivery efficiency over conventional "GenC2" and "GenC2M" in non-human primate (NHP) models.When Han's structural biology expertise and his AI-based capsid design technology are combined, ZenixCure expects to create strong synergy in the process of global commercialization and technology transfer (L/O) as well as design and optimization of new AAV capsids.GenixCure is actively expanding global technology transfer and co-development opportunities based on its own next-generation AAV vector platform and new capsid technology. Han will lead the establishment of global partnerships and commercialization of technology."Our company is securing global competitiveness based on AI-based AAV platform technology and next-generation CNS target vectors," said Moon Hong-sung, CEO of GenixCure. "By joining CEO Han Sung-il, we will connect R&D performance to commercialization performance and accelerate global technology transfer and strategic partnership expansion to become a global AAV platform company."[View Article]
-
NEWS
2026-05-22
GenixCure unveils AI-powered next-generation AAV capsid...
- Genixcure unveils next-generation AAV capsid research results based on AI and primate validation at ASGCT 2026- Multiple 2nd-generation GenC2·GenC2M variants secured with up to 30-fold improved transduction efficiency over parental capsids- Proprietary in vitro receptor-mediated screening system established with cross-species validation in human and non-human primate models- Platform value demonstrated with 180-fold improvement in BBB penetration and 64-fold increase in transferrin shuttle activity[View Article]
TOP